Understand the source comparison
Adrenomedullin vs Intermedin (Adrenomedullin-2) — Peptide Comparison
Adrenomedullin vs Intermedin (Adrenomedullin-2) — Peptide Comparison Adrenomedullin vs Intermedin (Adrenomedullin-2) — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for… At a Glance Dose Range Adrenomed
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
Adrenomedullin vs Intermedin (Adrenomedullin-2) — Peptide Comparison Adrenomedullin vs Intermedin (Adrenomedullin-2) — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for… At a Glance Dose Range Adrenomedullin As prescribed–As prescribed mg Intermedin (Adrenomedullin-2) Frequency Once daily Administration Intravenous infusion As directed by healthcare provider Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Limited human trials Efficacy Cardiovascular Support Tissue Protection Immune Function Cardiovascular Health & Protection Stress & Anxiety Management Anti-Inflammatory & Antioxidant Support Technical Data Molecular Formula C264H406N80O77S3 Molecular Weight 6029 Da (Daltons) Half-Life Approximately 20-30 minutes in plasma (rapid metabolism) Bioavailability Parenteral administration only; peptide undergoes proteolytic cleavage in circulation CAS Number 148498-78-6 C15H25NO5 (precursor compound) 299.36 g/mol (precursor) Approximately 2-6 hours (varies by route of administration) Varies by route of administration Protocols starting 5 ng/kg/min Continuous infusion, 8 hours per day 14 days (trial protocol) Adrenomedullin is given as a slow drip into a vein in clinical trials, not by self-injection. This low dose was the bottom step tested for steroid-resistant ulcerative colitis. [4] standard 10 ng/kg/min Middle dose tested in the ulcerative colitis trial. [4] advanced 15 ng/kg/min This higher dose was the only one that significantly improved disease scores in the trial. The same 15 ng/kg/min rate was also tested safely in healthy volunteers. [4][5] Applications Cardiovascular health optimization Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Maintaining healthy blood pressure Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Recovery from illness or sepsis Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Tissue protection and oxygen delivery Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting cardiovascular health and heart function Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing inflammation and oxidative stress Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Improving overall vascular health and circulation Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Mild discomfort at treatment site Excessive blood pressure lowering (hypotension) Headaches (from pressure changes) Flushing and mild facial redness Dizziness or lightheadedness Mild electrolyte shifts Localized injection site reactions Increased urination (natriuretic effect) Serious Severe allergic reaction Mild headache Injection site reactions (redness, itching, swelling) Nausea or mild gastrointestinal discomfort Fatigue or mild energy changes Transient hypotension (temporary low blood pressure) Mild palpitations (in some individuals) Research Status FDA Status Research compound Safety Overview Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses. Contraindications xSevere hypotension or shock states xConcurrent use with certain vasopressor medications xPregnancy and breastfeeding xSevere kidney or liver dysfunction Not FDA approved Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts. xPregnancy and breastfeeding - insufficient safety data xActive cardiovascular events (heart attack, stroke) xSevere renal (kidney) impairment xHypersensitivity to calcitonin family peptides xUncontrolled endocrine disorders Decision Guide Choose Adrenomedullin if... Cardiovascular health optimization Maintaining healthy blood pressure Recovery from illness or sepsis Tissue protection and oxygen delivery Choose Intermedin (Adrenomedullin-2) if... Supporting cardiovascular health and heart function Managing inflammation and oxidative stress Improving overall vascular health and circulation